Home › Upcoming votes › Jasper Therapeutics, Inc.
The deadline as the proxy statement states it: “Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern Time, on November 12, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Jasper Therapeutics, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | MERGER CONVERSION PROPOSAL | Board | For | — |
| 2 | PIPE CONVERSION PROPOSAL | Board | For | — |
| 3 | DIRECTOR RATIFICATION PROPOSAL | Board | For | — |
| 4 | ADJOURNMENT PROPOSAL Adjournment |
Board | For | — |
From Jasper Therapeutics, Inc.’s Form 8-K, filed July 3, 2025, for the meeting held July 3, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Kurt von Emster | 98% | — |
| Elect Director: Scott Brun, M.D. | 99.5% | — |
| Elect Director: Vishal Kapoor | 99.0% | — |
| 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal yea | 99.8% | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers | 94% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.